Alembic Pharmaceuticals, Inc., the U.S. subsidiary of Alembic Pharmaceuticals Ltd., has acquired Utility Therapeutics in a $12 million deal to strengthen its presence in the U.S. market.
Alembic will begin the commercialization of Utility’s recently FDA-approved product Pivya (pivmethecillam) for the treatment of uncomplicated urinary tract infections. Pivya was approved by the FDA in April 2024.
Pranav Amin, Managing Director of Alembic Pharmaceuticals, said, “This acquisition gives us a strategic entry into the specialty and branded prescription products. This will give us exposure to the branded pharmaceutical market with a near-term commercial launch.”
Tom Hadley, President and CEO of UTILITY Therapeutics, said, “We are thrilled that Alembic Pharmaceuticals understands the clinical and commercial value of PIVYA and will bring this proven treatment to female patients in need across the U.S. With current therapies failing and the armament of uUTI antibiotics perilously thin, PIVYA provides U.S. clinicians with a new and effective treatment option that has a long safety record.”
Craig Salmon, President of Alembic Pharmaceuticals, Inc., said, “Since 2015, Alembic Pharmaceuticals US has grown its generics business to over 160 molecules and 413 products, including generic dermaceutical, ophthalmic, general injectable, and oncology products. Entering the branded product market is the next phase of our US growth. Pivya represents an important and much-needed treatment option for patients with uncomplicated urinary tract infections. It has an excellent history for safety, effectiveness and low levels of bacterial resistance in Europe for 40 years of real-world experience. The acquisition of Utility broadens Alembic Inc’s footprint beyond generic pharmaceuticals and will allow Alembic to build out its capabilities in the large US branded pharmaceutical market. We plan to have PIVYA available in the US in Q4, 2025.”
